Baxter GMP Warning Letter Driven By Rainbow Of Tablet Colors
This article was originally published in The Pink Sheet Daily
Executive Summary
Baxter HealthCare's Puerto Rico manufacturing facilities were turning out such quantities of discolored drugs the company produced a color chart telling end users when to discard them.
You may also be interested in...
GMP Warning Letter: Teva Preempts FDA In Disclosing Problems At Jerusalem Plant
Generic giant Teva took the unusual step of disclosing the entire contents of a Jan. 31 FDA warning letter about good manufacturing process failings, as part of a Securities and Exchange Commission filing it posted online two days later.
GMP Warning Letter: Teva Preempts FDA In Disclosing Problems At Jerusalem Plant
Generic giant Teva took the unusual step of disclosing the entire contents of a Jan. 31 FDA warning letter about good manufacturing process failings, as part of a Securities and Exchange Commission filing it posted online two days later.
GMP Closeout "Carrots" Sprout; Baxter Receives First, But FDA Is Subdued
If the first-ever FDA closeout letter to an Rx manufacturer is any indication, the correspondence may not offer a clear-cut end to compliance issues cited in warning letters